Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections.
Yang J, Won G, Baek JY, Lee YH, Kim H, Huh K, Cho SY, Kang CI, Chung DR, Peck KR, Lee KW, Park JB, Yoon SE, Kim SJ, Kim WS, Yim MS, Kim K, Hyeon S, Kim BC, Lee YK, Ko JH.
Yang J, et al. Among authors: won g.
Front Immunol. 2023 Mar 2;14:1139980. doi: 10.3389/fimmu.2023.1139980. eCollection 2023.
Front Immunol. 2023.
PMID: 36936968
Free PMC article.